MX2009003771A - Formulaciones robustas de liberacion sostenida. - Google Patents

Formulaciones robustas de liberacion sostenida.

Info

Publication number
MX2009003771A
MX2009003771A MX2009003771A MX2009003771A MX2009003771A MX 2009003771 A MX2009003771 A MX 2009003771A MX 2009003771 A MX2009003771 A MX 2009003771A MX 2009003771 A MX2009003771 A MX 2009003771A MX 2009003771 A MX2009003771 A MX 2009003771A
Authority
MX
Mexico
Prior art keywords
sustained release
release formulations
formulations
robust
robust sustained
Prior art date
Application number
MX2009003771A
Other languages
English (en)
Spanish (es)
Inventor
Anand R Baichwal
Steve Labudzinski
Kevin Fitzmaurice
Original Assignee
Penwest Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penwest Pharmaceuticals Co filed Critical Penwest Pharmaceuticals Co
Publication of MX2009003771A publication Critical patent/MX2009003771A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2009003771A 2006-10-10 2006-10-10 Formulaciones robustas de liberacion sostenida. MX2009003771A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/039923 WO2008045060A1 (en) 2006-10-10 2006-10-10 Robust sustained release formulations

Publications (1)

Publication Number Publication Date
MX2009003771A true MX2009003771A (es) 2009-07-22

Family

ID=38048029

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003771A MX2009003771A (es) 2006-10-10 2006-10-10 Formulaciones robustas de liberacion sostenida.

Country Status (10)

Country Link
EP (1) EP2079453A1 (pt)
JP (1) JP5422388B2 (pt)
KR (1) KR20090113243A (pt)
CN (1) CN101578096A (pt)
AU (1) AU2006349402A1 (pt)
BR (1) BRPI0621947A2 (pt)
CA (1) CA2652981C (pt)
IL (1) IL198168A0 (pt)
MX (1) MX2009003771A (pt)
WO (1) WO2008045060A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130297A1 (en) 2001-07-06 2003-07-10 Endo Pharmaceuticals, Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
TWI473628B (zh) 2009-07-22 2015-02-21 用於對氧化敏感之類鴉片藥劑之抗破壞劑型
CN103269688A (zh) 2010-09-02 2013-08-28 格吕伦塔尔有限公司 包含无机盐的抗破碎剂型
NO2736495T3 (pt) 2011-07-29 2018-01-20
NO2736497T3 (pt) 2011-07-29 2018-01-20
TW201343201A (zh) 2012-03-06 2013-11-01 Otsuka Pharma Co Ltd 持續釋放型口服固體製劑
RS57913B1 (sr) 2012-04-18 2019-01-31 Gruenenthal Gmbh Farmaceutske dozne forme otporne na neovlašćenu upotrebu i naglo oslobađanje celokupne doze
EP3019157A1 (en) 2013-07-12 2016-05-18 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
EA201692388A1 (ru) * 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
CN104622791A (zh) * 2015-02-13 2015-05-20 扬子江药业集团有限公司 地佐辛口服制剂
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
US20170296476A1 (en) * 2016-04-15 2017-10-19 Grünenthal GmbH Modified release abuse deterrent dosage forms
KR102380498B1 (ko) * 2021-02-24 2022-04-01 주식회사 청안오가닉스 건강기능식품에 있어서 유효성분의 지속적인 방출을 제어할 수 있는 서방형 정제를 제조하기 위한 조성물
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
US5169639A (en) * 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
FR2729857B1 (fr) * 1995-01-27 1997-04-04 Rhone Poulenc Chimie Compositions pharmaceutiques sous forme de comprimes a liberation prolongee a base de granules en polysaccharides de haut poids moleculaire
US5904937A (en) * 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions
GR1003560B (el) * 1999-04-13 2001-03-16 Beecham Pharmaceuticals (Pte) Limited Σκευασματα τροποποιημενης απελευθερωσης αμοξυκιλλινης και κλαβουλανικου καλιου
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
US20030130297A1 (en) * 2001-07-06 2003-07-10 Endo Pharmaceuticals, Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
EP1404331B1 (en) * 2001-07-06 2007-10-31 Penwest Pharmaceuticals Co. Sustained release formulations of oxymorphone
US20030091635A1 (en) * 2001-09-26 2003-05-15 Baichwal Anand R. Opioid formulations having reduced potential for abuse
US20060193912A1 (en) * 2005-02-28 2006-08-31 Penwest Pharmaceuticals Co. Controlled release O-desmethylvenlafaxine formulations

Also Published As

Publication number Publication date
WO2008045060A1 (en) 2008-04-17
KR20090113243A (ko) 2009-10-29
BRPI0621947A2 (pt) 2011-10-18
AU2006349402A1 (en) 2008-04-17
CN101578096A (zh) 2009-11-11
CA2652981A1 (en) 2008-04-17
CA2652981C (en) 2012-05-01
EP2079453A1 (en) 2009-07-22
JP5422388B2 (ja) 2014-02-19
IL198168A0 (en) 2009-12-24
JP2010505949A (ja) 2010-02-25

Similar Documents

Publication Publication Date Title
MX2009003771A (es) Formulaciones robustas de liberacion sostenida.
MX2008011823A (es) Forma de dosificacion solida que contiene un agente activo de sabor encubierto.
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
WO2007095600A3 (en) Disintegrable oral films
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
NO20070887L (no) Kornformet farmasoytisk preparat med tidsbegrenset frigivelse for oral administrasjon, og intraoral hurtig desintegrerende tablett som inneholder preparatet
WO2007103293A3 (en) Ethanol-resistant sustained release formulations
WO2008085765A3 (en) Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
EP2248519A3 (en) Non-mucoadhesive film dosage forms
MX2010000803A (es) Formulaciones de analgesicos no opioides y opioides confinados.
WO2010062688A3 (en) Dosage form for insertion into the mouth
WO2007143155A3 (en) Sustained release pharmaceutical dosage form containing phenylephrine
NZ592276A (en) PHARMACEUTICAL DOSAGE FORMS COMPRISING POLY(epsilon-CAPROLACTONE) AND AN OPIOID
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
IL220722A (en) Use of fentanyl for the preparation of a rapid-release pharmacological preparation for eruptive pain and a biodegradable device for providing the mucosal pathway that is suitable for direct delivery through the mantle of the fentile
UA104745C2 (ru) Оральная фармацевтическая дозированная форма, защищенная от несанкционированного использования, содержащая опиоидный анальгетик
IL179896A (en) Opioid with a delayed oral dosage form containing a mixture of opioid agonist and antagonist for use in the treatment of nervous leg syndrome
MX2013009773A (es) Vehiculo masticable para absorcion bucal.
JP2009522376A5 (pt)
WO2007106550A3 (en) Methods and compositions for deterring abuse of orally administered pharmaceutical products
WO2007018588A8 (en) Stable pharmaceutical composition comprising linezolid form iv
MX2009009132A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona.
WO2007123865A3 (en) Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists
NZ628513A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
WO2007146805A3 (en) Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailabilty